Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.

Gille A, Duffy D, Tortorici MA, Wright SD, Deckelbaum LI, D'Andrea DM.

J Clin Pharmacol. 2019 Mar;59(3):427-436. doi: 10.1002/jcph.1337. Epub 2018 Nov 19.

PMID:
30452776
2.

Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function.

Tortorici MA, Duffy D, Evans R, Feaster J, Gille A, Mant TGK, Wright SD, D'Andrea D.

Clin Pharmacol Drug Dev. 2018 Sep 21. doi: 10.1002/cpdd.618. [Epub ahead of print]

PMID:
30240132
3.

Circulating HDL levels control hypothalamic astrogliosis via apoA-I.

Götz A, Lehti M, Donelan E, Striese C, Cucuruz S, Sachs S, Yi CX, Woods SC, Wright SD, Müller TD, Tschöp MH, Gao Y, Hofmann SM.

J Lipid Res. 2018 Sep;59(9):1649-1659. doi: 10.1194/jlr.M085456. Epub 2018 Jul 10.

PMID:
29991652
4.

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.

Gurbel PA, Tantry US, D'Andrea D, Chung T, Alexander JH, Bliden KP, Wright SD, Tricoci P.

J Thromb Thrombolysis. 2018 May;45(4):469-476. doi: 10.1007/s11239-018-1644-z.

5.

CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.

Gille A, D'Andrea D, Tortorici MA, Hartel G, Wright SD.

Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):953-963. doi: 10.1161/ATVBAHA.118.310538. Epub 2018 Feb 8.

6.

Antibiotic overprescribing: Still a major concern.

Fiore DC, Fettic LP, Wright SD, Ferrara BR.

J Fam Pract. 2017 Dec;66(12):730-736.

PMID:
29202142
7.

Temporal patterns of chronic wasting disease prion excretion in three cervid species.

Plummer IH, Wright SD, Johnson CJ, Pedersen JA, Samuel MD.

J Gen Virol. 2017 Jul;98(7):1932-1942. doi: 10.1099/jgv.0.000845. Epub 2017 Jul 15.

PMID:
28708047
8.

Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.

Cukier AMO, Therond P, Didichenko SA, Guillas I, Chapman MJ, Wright SD, Kontush A.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):890-900. doi: 10.1016/j.bbalip.2017.05.010. Epub 2017 May 18.

PMID:
28529180
9.

A Consensus Definitive Classification of Scavenger Receptors and Their Roles in Health and Disease.

PrabhuDas MR, Baldwin CL, Bollyky PL, Bowdish DME, Drickamer K, Febbraio M, Herz J, Kobzik L, Krieger M, Loike J, McVicker B, Means TK, Moestrup SK, Post SR, Sawamura T, Silverstein S, Speth RC, Telfer JC, Thiele GM, Wang XY, Wright SD, El Khoury J.

J Immunol. 2017 May 15;198(10):3775-3789. doi: 10.4049/jimmunol.1700373.

10.

Multi-Phase US Spread and Habitat Switching of a Post-Columbian Invasive, Sorghum halepense.

Sezen UU, Barney JN, Atwater DZ, Pederson GA, Pederson JF, Chandler JM, Cox TS, Cox S, Dotray P, Kopec D, Smith SE, Schroeder J, Wright SD, Jiao Y, Kong W, Goff V, Auckland S, Rainville LK, Pierce GJ, Lemke C, Compton R, Phillips C, Kerr A, Mettler M, Paterson AH.

PLoS One. 2016 Oct 18;11(10):e0164584. doi: 10.1371/journal.pone.0164584. eCollection 2016.

11.

Autism aging.

Wright SD, Wright CA, D'Astous V, Wadsworth AM.

Gerontol Geriatr Educ. 2016 Oct 17:1-17. doi: 10.1080/02701960.2016.1247073. [Epub ahead of print]

PMID:
27749163
12.

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.

Didichenko SA, Navdaev AV, Cukier AM, Gille A, Schuetz P, Spycher MO, Thérond P, Chapman MJ, Kontush A, Wright SD.

Circ Res. 2016 Sep 2;119(6):751-63. doi: 10.1161/CIRCRESAHA.116.308685. Epub 2016 Jul 19.

13.

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.

Zimmer S, Grebe A, Bakke SS, Bode N, Halvorsen B, Ulas T, Skjelland M, De Nardo D, Labzin LI, Kerksiek A, Hempel C, Heneka MT, Hawxhurst V, Fitzgerald ML, Trebicka J, Björkhem I, Gustafsson JÅ, Westerterp M, Tall AR, Wright SD, Espevik T, Schultze JL, Nickenig G, Lütjohann D, Latz E.

Sci Transl Med. 2016 Apr 6;8(333):333ra50. doi: 10.1126/scitranslmed.aad6100.

14.

Reconstituted high-density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component.

Herzog E, Pragst I, Waelchli M, Gille A, Schenk S, Mueller-Cohrs J, Diditchenko S, Zanoni P, Cuchel M, Seubert A, Rader DJ, Wright SD.

J Appl Toxicol. 2016 Aug;36(8):1038-47. doi: 10.1002/jat.3264. Epub 2015 Dec 9.

PMID:
26651060
15.

Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.

Robert J, Stukas S, Button E, Cheng WH, Lee M, Fan J, Wilkinson A, Kulic I, Wright SD, Wellington CL.

Biochim Biophys Acta. 2016 May;1862(5):1027-36. doi: 10.1016/j.bbadis.2015.10.005. Epub 2015 Oct 9.

16.

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.

Tricoci P, D'Andrea DM, Gurbel PA, Yao Z, Cuchel M, Winston B, Schott R, Weiss R, Blazing MA, Cannon L, Bailey A, Angiolillo DJ, Gille A, Shear CL, Wright SD, Alexander JH.

J Am Heart Assoc. 2015 Aug 25;4(8):e002171. doi: 10.1161/JAHA.115.002171.

17.

Reconstituted High-Density Lipoprotein Attenuates Cholesterol Crystal-Induced Inflammatory Responses by Reducing Complement Activation.

Niyonzima N, Samstad EO, Aune MH, Ryan L, Bakke SS, Rokstad AM, Wright SD, Damås JK, Mollnes TE, Latz E, Espevik T.

J Immunol. 2015 Jul 1;195(1):257-64. doi: 10.4049/jimmunol.1403044. Epub 2015 May 29.

18.

Time for living and caring: an intervention to make respite more effective for caregivers.

Lund DA, Utz RL, Caserta MS, Wright SD, Llanque SM, Lindfelt C, Shon H, Whitlatch CJ, Montoro-Rodriguez J.

Int J Aging Hum Dev. 2014;79(2):157-78.

19.

CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.

Gille A, Easton R, D'Andrea D, Wright SD, Shear CL.

Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2106-14. doi: 10.1161/ATVBAHA.114.303720. Epub 2014 Jun 26.

PMID:
24969776
20.

Gray and green revisited: a multidisciplinary perspective of gardens, gardening, and the aging process.

Wright SD, Wadsworth AM.

J Aging Res. 2014;2014:283682. doi: 10.1155/2014/283682. Epub 2014 Mar 6. Review.

21.

Evidence base for using atypical antipsychotics for psychosis in adolescents.

Datta SS, Kumar A, Wright SD, Furtado VA, Russell PS.

Schizophr Bull. 2014 Mar;40(2):252-4. doi: 10.1093/schbul/sbt196. Epub 2013 Dec 20. Review.

22.

High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3.

De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, Xu D, Zimmer S, Lahrmann C, Schildberg FA, Vogelhuber J, Kraut M, Ulas T, Kerksiek A, Krebs W, Bode N, Grebe A, Fitzgerald ML, Hernandez NJ, Williams BR, Knolle P, Kneilling M, Röcken M, Lütjohann D, Wright SD, Schultze JL, Latz E.

Nat Immunol. 2014 Feb;15(2):152-60. doi: 10.1038/ni.2784. Epub 2013 Dec 8.

23.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
24.

A multiple ascending dose study of CSL112, an infused formulation of ApoA-I.

Easton R, Gille A, D'Andrea D, Davis R, Wright SD, Shear C.

J Clin Pharmacol. 2014 Mar;54(3):301-10. doi: 10.1002/jcph.194. Epub 2013 Oct 22.

PMID:
24122814
25.

Diagnostic stages of the parasites of the Florida manatee, Trichechus manatus latirostris.

Bando M, Larkin IV, Wright SD, Greiner EC.

J Parasitol. 2014 Feb;100(1):133-8. doi: 10.1645/13-206.1. Epub 2013 Oct 11.

PMID:
24116863
26.

Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.

Diditchenko S, Gille A, Pragst I, Stadler D, Waelchli M, Hamilton R, Leis A, Wright SD.

Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2202-11. doi: 10.1161/ATVBAHA.113.301981. Epub 2013 Jul 18.

PMID:
23868939
27.

A conservative and fertility preserving treatment for interstitial ectopic pregnancy.

Wright SD, Busbridge RC, Gard GB.

Aust N Z J Obstet Gynaecol. 2013 Apr;53(2):211-3. doi: 10.1111/ajo.12067.

PMID:
23577788
28.

Evolution and spread of glyphosate resistance in Conyza canadensis in California.

Okada M, Hanson BD, Hembree KJ, Peng Y, Shrestha A, Stewart CN Jr, Wright SD, Jasieniuk M.

Evol Appl. 2013 Mar 11;6(5):761-777. doi: 10.1111/eva.12061. eCollection 2013 Jul.

29.

Inheritance and QTL mapping of Fusarium wilt race 4 resistance in cotton.

Ulloa M, Hutmacher RB, Roberts PA, Wright SD, Nichols RL, Michael Davis R.

Theor Appl Genet. 2013 May;126(5):1405-18. doi: 10.1007/s00122-013-2061-5. Epub 2013 Mar 8.

PMID:
23471458
30.

What is the form of the productivity-animal-species-richness relationship? A critical review and meta-analysis.

Cusens J, Wright SD, McBride PD, Gillman LN.

Ecology. 2012 Oct;93(10):2241-52. Review.

PMID:
23185885
31.

Grandparents of grandchildren with autism spectrum disorders (ASD): strengthening relationships through technology activities.

Wright SD, D'Astous V, Wright CA, Diener ML.

Int J Aging Hum Dev. 2012;75(2):169-84.

PMID:
23185859
32.

11β-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature.

Luo MJ, Thieringer R, Springer MS, Wright SD, Hermanowski-Vosatka A, Plump A, Balkovec JM, Cheng K, Ding GJ, Kawka DW, Koo GC, Grand CB, Luo Q, Maletic MM, Malkowitz L, Shah K, Singer I, Waddell ST, Wu KK, Yuan J, Zhu J, Stepaniants S, Yang X, Lum PY, Wang IM.

Physiol Genomics. 2013 Jan 7;45(1):47-57. doi: 10.1152/physiolgenomics.00109.2012. Epub 2012 Nov 20.

PMID:
23170035
33.

Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.

Lauring B, Taggart AK, Tata JR, Dunbar R, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo WL, Maclean AA, Peterson LB, Polis AB, Sirah W, Wu TJ, Liu X, Jin L, Wu K, Boatman PD, Semple G, Behan DP, Connolly DT, Lai E, Wagner JA, Wright SD, Cuffie C, Mitchel YB, Rader DJ, Paolini JF, Waters MG, Plump A.

Sci Transl Med. 2012 Aug 22;4(148):148ra115. doi: 10.1126/scitranslmed.3003877.

34.

Discovery of pyrazole carboxylic acids as potent inhibitors of rat long chain L-2-hydroxy acid oxidase.

Barawkar DA, Bandyopadhyay A, Deshpande A, Koul S, Kandalkar S, Patil P, Khose G, Vyas S, Mone M, Bhosale S, Singh U, De S, Meru A, Gundu J, Chugh A, Palle VP, Mookhtiar KA, Vacca JP, Chakravarty PK, Nargund RP, Wright SD, Roy S, Graziano MP, Cully D, Cai TQ, Singh SB.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4341-7. doi: 10.1016/j.bmcl.2012.05.020. Epub 2012 May 11.

PMID:
22658862
35.

Potent and Selective Inhibitors of Long Chain l-2-Hydroxy Acid Oxidase Reduced Blood Pressure in DOCA Salt-Treated Rats.

Barawkar DA, Meru A, Bandyopadhyay A, Banerjee A, Deshpande AM, Athare C, Koduru C, Khose G, Gundu J, Mahajan K, Patil P, Kandalkar SR, Niranjan S, Bhosale S, De S, Mukhopadhyay S, Chaudhary S, Koul S, Singh U, Chugh A, Palle VP, Mookhtiar KA, Vacca J, Chakravarty PK, Nargund RP, Wright SD, Roy S, Graziano MP, Singh SB, Cully D, Cai TQ.

ACS Med Chem Lett. 2011 Oct 7;2(12):919-23. doi: 10.1021/ml2001938. eCollection 2011 Dec 8.

36.

SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors.

Lu Z, Chen YH, Napolitano JB, Taylor G, Ali A, Hammond ML, Deng Q, Tan E, Tong X, Xu SS, Latham MJ, Peterson LB, Anderson MS, Eveland SS, Guo Q, Hyland SA, Milot DP, Chen Y, Sparrow CP, Wright SD, Sinclair PJ.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):199-203. doi: 10.1016/j.bmcl.2011.11.039. Epub 2011 Nov 16.

PMID:
22142541
37.

Reconstituted HDL elicits marked changes in plasma lipids following single-dose injection in C57Bl/6 mice.

Chen Z, O'Neill EA, Meurer RD, Gagen K, Luell S, Wang SP, Ichetovkin M, Frantz-Wattley B, Eveland S, Strack AM, Fisher TS, Johns DG, Sparrow CP, Wright SD, Hubbard BK, Carballo-Jane E.

J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):315-23. doi: 10.1177/1074248411426144. Epub 2011 Nov 8.

PMID:
22067613
38.

A gene expression signature that classifies human atherosclerotic plaque by relative inflammation status.

Puig O, Yuan J, Stepaniants S, Zieba R, Zycband E, Morris M, Coulter S, Yu X, Menke J, Woods J, Chen F, Ramey DR, He X, O'Neill EA, Hailman E, Johns DG, Hubbard BK, Yee Lum P, Wright SD, Desouza MM, Plump A, Reiser V.

Circ Cardiovasc Genet. 2011 Dec;4(6):595-604. doi: 10.1161/CIRCGENETICS.111.960773. Epub 2011 Oct 18.

PMID:
22010137
39.

Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.

Smith CJ, Ali A, Hammond ML, Li H, Lu Z, Napolitano J, Taylor GE, Thompson CF, Anderson MS, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Sparrow CP, Wright SD, Cumiskey AM, Latham M, Peterson LB, Rosa R, Pivnichny JV, Tong X, Xu SS, Sinclair PJ.

J Med Chem. 2011 Jul 14;54(13):4880-95. doi: 10.1021/jm200484c. Epub 2011 Jun 17.

PMID:
21682257
40.

Discovery of substituted biphenyl oxazolidinone inhibitors of cholesteryl ester transfer protein.

Thompson CF, Ali A, Quraishi N, Lu Z, Hammond ML, Sinclair PJ, Anderson MS, Eveland SS, Guo Q, Hyland SA, Milot DP, Sparrow CP, Wright SD.

ACS Med Chem Lett. 2011 Mar 24;2(6):424-7. doi: 10.1021/ml100309n. eCollection 2011 Jun 9.

41.

Discovery of a potent and selective small molecule hGPR91 antagonist.

Bhuniya D, Umrani D, Dave B, Salunke D, Kukreja G, Gundu J, Naykodi M, Shaikh NS, Shitole P, Kurhade S, De S, Majumdar S, Reddy SB, Tambe S, Shejul Y, Chugh A, Palle VP, Mookhtiar KA, Cully D, Vacca J, Chakravarty PK, Nargund RP, Wright SD, Graziano MP, Singh SB, Roy S, Cai TQ.

Bioorg Med Chem Lett. 2011 Jun 15;21(12):3596-602. doi: 10.1016/j.bmcl.2011.04.091. Epub 2011 Apr 28.

PMID:
21571530
42.

Mapping Fusarium wilt race 1 resistance genes in cotton by inheritance, QTL and sequencing composition.

Ulloa M, Wang C, Hutmacher RB, Wright SD, Davis RM, Saski CA, Roberts PA.

Mol Genet Genomics. 2011 Jul;286(1):21-36. doi: 10.1007/s00438-011-0616-1. Epub 2011 May 1.

PMID:
21533837
43.

2-(4-carbonylphenyl)benzoxazole inhibitors of CETP: scaffold design and advancement in HDLc-raising efficacy.

Sweis RF, Hunt JA, Kallashi F, Hammond ML, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Cumiskey AM, Latham M, Rosa R, Peterson L, Sparrow CP, Wright SD, Anderson MS, Sinclair PJ.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1890-5. doi: 10.1016/j.bmcl.2010.11.090. Epub 2010 Nov 25.

PMID:
21147531
44.

2-Arylbenzoxazoles as CETP inhibitors: raising HDL-C in cynoCETP transgenic mice.

Kallashi F, Kim D, Kowalchick J, Park YJ, Hunt JA, Ali A, Smith CJ, Hammond ML, Pivnichny JV, Tong X, Xu SS, Anderson MS, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Cumiskey AM, Latham M, Peterson LB, Rosa R, Sparrow CP, Wright SD, Sinclair PJ.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):558-61. doi: 10.1016/j.bmcl.2010.10.062. Epub 2010 Oct 20.

PMID:
21094047
45.

Design of a novel class of biphenyl CETP inhibitors.

Lu Z, Napolitano JB, Theberge A, Ali A, Hammond ML, Tan E, Tong X, Xu SS, Latham MJ, Peterson LB, Anderson MS, Eveland SS, Guo Q, Hyland SA, Milot DP, Chen Y, Sparrow CP, Wright SD, Sinclair PJ.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7469-72. doi: 10.1016/j.bmcl.2010.10.019. Epub 2010 Oct 15.

PMID:
21041082
46.

Mega mistakes in meta-analyses: devil in the detail.

Gillman LN, Wright SD.

Ecology. 2010 Sep;91(9):2550-2. No abstract available.

PMID:
20957947
47.

Faster evolution of highly conserved DNA in tropical plants.

Gillman LN, Keeling DJ, Gardner RC, Wright SD.

J Evol Biol. 2010 Jun 1;23(6):1327-30. doi: 10.1111/j.1420-9101.2010.01992.x. Epub 2010 Apr 23.

48.

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.

Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E.

Nature. 2010 Apr 29;464(7293):1357-61. doi: 10.1038/nature08938. Erratum in: Nature. 2010 Jul 29;466(7306):652.

49.

2-Arylbenzoxazoles as CETP inhibitors: substitution and modification of the alpha-alkoxyamide moiety.

Hunt JA, Gonzalez S, Kallashi F, Hammond ML, Pivnichny JV, Tong X, Xu SS, Anderson MS, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Sparrow CP, Wright SD, Sinclair PJ.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1019-22. doi: 10.1016/j.bmcl.2009.12.046. Epub 2009 Dec 16.

PMID:
20036121
50.

2-Arylbenzoxazoles as CETP inhibitors: Substitution of the benzoxazole moiety.

Smith CJ, Ali A, Chen L, Hammond ML, Anderson MS, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Sparrow CP, Wright SD, Sinclair PJ.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):346-9. doi: 10.1016/j.bmcl.2009.10.099. Epub 2009 Oct 29. Erratum in: Bioorg Med Chem Lett. 2010 Dec 15;20(24):7555.

PMID:
19914065

Supplemental Content

Loading ...
Support Center